Makiren (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside skin cells, altering gene transcription. This suppresses the production of inflammatory mediators, reduces leukocyte migration, and limits vascular leakage, providing a potent anti‑inflammatory and immunosuppressive effect on the skin.

The appropriate dose of Makiren is determined by the prescribing healthcare professional based on the severity of the skin condition, the area to be treated and patient‑specific factors. No fixed regimen is provided here; the prescriber sets the regimen.

Safety data for mometasone furoate in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To request Makiren, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a high‑potency corticosteroid, offering stronger anti‑inflammatory activity than low‑potency agents such as hydrocortisone. Compared with other high‑potency steroids like clobetasol, it provides similar efficacy with a slightly lower risk of systemic absorption when used as directed.

Makiren should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children.

Apply a thin layer of Makiren to the affected skin area once daily or as directed by a healthcare professional. Gently rub the product until it disappears, avoid contact with eyes, and wash hands after application unless the hands are the treatment site.

Serious risks include hypothalamic‑pituitary‑adrenal (HPA) axis suppression, severe skin atrophy or striae, and secondary bacterial, fungal or viral infections of the treated area. These events are uncommon but require prompt medical evaluation if they occur.

Makiren should be avoided in individuals with known hypersensitivity to mometasone furoate or any formulation excipients, in patients with untreated skin infections, and in those for whom systemic corticosteroid therapy is contraindicated unless specifically advised by a physician.